Phase 3 Clinical Trials With Primary Completion Dates in March 2016
This is a list of Phase 3 trials with primary completion dates in March 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AMAG | AMAG Pharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT01155375 | A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease |
| CPXX | Celator Pharmaceuticals Inc. | 2016-03-01 | Phase 3 | NCT01696084 | Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia |
| DERM | Dermira, Inc. | 2016-03-01 | Phase 3 | NCT02326298 | An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) |
| DPRX | Dipexium Pharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT01594762 | Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers |
| DPRX | Dipexium Pharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT01590758 | Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers |
| DSCI | Derma Sciences, Inc. | 2016-03-01 | Phase 3 | NCT01849965 | Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers |
| DSCI | Derma Sciences, Inc. | 2016-03-01 | Phase 3 | NCT01830348 | Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers |
| EARS | Auris Medical Holding AG | 2016-03-01 | Phase 3 | NCT01803646 | AM-101 in the Treatment of Acute Tinnitus 2 |
| ENDP | Endo International plc | 2016-03-01 | Phase 3 | NCT02267460 | An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease |
| FLXN | Flexion Therapeutics, Inc. | 2016-03-01 | Phase 3 | NCT02357459 | Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee |
| INNL | Innocoll AG | 2016-03-01 | Phase 3 | NCT02525133 | Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty |
| INNL | Innocoll AG | 2016-03-01 | Phase 3 | NCT02523599 | Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty |
| LXRX | Lexicon Pharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT02063659 | Telotristat Etiprate for Carcinoid Syndrome Therapy |
| LXRX | Lexicon Pharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT01677910 | TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) |
| MNK | Mallinckrodt plc | 2016-03-01 | Phase 3 | NCT01709721 | Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump |
| MYGN | Myriad Genetics, Inc. | 2016-03-01 | Phase 3 | NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer |
| NAVB | Navidea Biopharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT01950468 | A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes |
| NAVB | Navidea Biopharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT01950455 | Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes |
| ONTX | Onconova Therapeutics, Inc. | 2016-03-01 | Phase 3 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
| RIGL | Rigel Pharmaceuticals, Inc. | 2016-03-01 | Phase 3 | NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| TSRO | TESARO, Inc. | 2016-03-01 | Phase 3 | NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer |